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Abstract: 
Introduction  
The conduct of structured benefit-risk assessment (BRA) of pharmaceutical 
products is a key area of interest for regulatory agencies and the 
pharmaceutical industry. However, the acceptance of a standardized 
approach and implementation are slow. Statisticians play major roles in 
these organizations, and have a great opportunity to be involved and drive 
the shaping of future BRA.  
 
Method  
We performed a literature search of recent reviews and initiatives 
assessing BRA methodologies, and grouped them to assist those new to 
BRA in learning, understanding, and choosing methodologies. We 
summarized the key points and discussed the impact of this emerging field 
on various stakeholders, particularly statisticians in the pharmaceutical 
industry.  
 
Results  
We provide introductory, essential, special interest, and further information 
and initiatives materials that direct readers to the most relevant materials, 
which were published between 2000 and 2013.  Based on 
recommendations in these materials we supply a toolkit of advocated BRA 
methodologies.  
Discussion  
Despite initiatives promoting these methodologies, there are still barriers, 
one of which being the lack of a consensus on the most appropriate 
methodologies. Further work is needed to convince various stakeholders. 
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But this opens up opportunities, for statisticians in the pharmaceutical 
industry especially, to champion appropriate BRA methodology use 
throughout the pharmaceutical product lifecycle.  
 
Conclusions  
This article may serve as a starting point for discussions and to reach a 
mutual consensus for methodology selection in a particular situation. 
Regulators and pharmaceutical industry should continue to collaborate to 
develop and take forward BRA methodologies, ensuring proper 
communication and mutual understanding.  
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Abstract 
 
Introduction 
The conduct of structured benefit-risk assessment (BRA) of pharmaceutical products is a key 
area of interest for regulatory agencies and the pharmaceutical industry. However, the 
acceptance of a standardized approach and implementation are slow. Statisticians play major 
roles in these organizations, and have a great opportunity to be involved and drive the 
shaping of future BRA. 
 
Method 
We performed a literature search of recent reviews and initiatives assessing BRA 
methodologies, and grouped them to assist those new to BRA in learning, understanding, and 
choosing methodologies. We summarized the key points and discussed the impact of this 
emerging field on various stakeholders, particularly statisticians in the pharmaceutical 
industry. 
 
Results 
We provide introductory, essential, special interest, and further information and initiatives 
materials that direct readers to the most relevant materials, which were published between 
2000 and 2013.  Based on recommendations in these materials we supply a toolkit of 
advocated BRA methodologies. 
Discussion 
Despite initiatives promoting these methodologies, there are still barriers, one of which being 
the lack of a consensus on the most appropriate methodologies. Further work is needed to 
convince various stakeholders. But this opens up opportunities, for statisticians in the 
pharmaceutical industry especially, to champion appropriate BRA methodology use 
throughout the pharmaceutical product lifecycle. 
 
Conclusions 
This article may serve as a starting point for discussions and to reach a mutual consensus for 
methodology selection in a particular situation. Regulators and pharmaceutical industry 
should continue to collaborate to develop and take forward BRA methodologies, ensuring 
proper communication and mutual understanding.  
 
  
Page 3 of 23
http://mc.manuscriptcentral.com/pst-wiley
Pharmaceutical Statistics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3 
 
Introduction 
Pharmaceutical products are prescribed to patients to treat and prevent many diseases. The 
efficacy of these products needs to be balanced with their safety profile.  The importance of 
considering unfavorable effects within the context of the product’s favorable effects is 
reflected in the position of the health authorities. Periodic Benefit-Risk Evaluation Report 
(PBRER) for post-marketing pharmacovigilance replaced, in April 2013,1,2 previous Periodic 
Safety Update Reports (PSUR). The US Food and Drug Administration (FDA) is now 
required to perform structured benefit risk assessment as part of the approval process, which 
is reflected in the reauthorized fifth Prescription Drug User Fee Act (PDUFA V).3,4  The 
European Medicines Agency (EMA) suggests the introduction of more quantitative elements, 
including taking into account direct patient preferences in benefit-risk assessment, and that 
regulators should shift towards a more explicit decision-making process and should focus 
more on quantitative descriptions of net health benefits.5 
 
Health technology assessors also require costs to be balanced against benefits and risks.
6-8
 For 
pharmaceutical companies, benefit-risk assessment is fundamental to decision-making and to 
designing development programs, not only to meet the regulatory requirements but also to 
show added value in view of their benefits and risks throughout the product development 
process and post-marketing surveillance. Although this process is complex, it is a necessary 
part of benefit-risk decision making, whether pronounced or not. Structured benefit-risk 
assessment can make processes transparent, and help with better informed decision-making;
9
 
and may additionally identify potential gaps in the evidence base.  As such, research shows 
that structured decision approaches can lead to better-informed decisions and can help policy 
decisions.
10
 
 
Benefit-risk assessment presents challenges and opportunities to statisticians in the 
pharmaceutical industry.11 Statisticians, who are experienced in benefit risk assessment, can 
drive the discussions with clinical colleagues, lead the translation of medical concepts into 
valid endpoints, analyze both favorable and unfavorable effects, and develop a strategy to 
assess the robustness of quantitative BRA models. It should be a key strength of statisticians 
to understand strengths and limitations of clinical trials, observational data, and other non-
clinical trial information sources potentially included in a benefit-risk model to transition the 
compound through the complete life-cycle. Therefore, statisticians need to combine their 
methodological rigor and strong technical knowledge with influencing skills in order to lead 
benefit-risk assessments in order to contribute to sound decisions for the treatment of 
patients.  
 
This article aims to facilitate fast and efficient learning by providing key information to 
researchers, particularly statisticians, who are new to the area of benefit-risk assessment. 
 
Methods 
In the last years, there have been many publications, reviews, and initiatives in this area. 
Therefore, we carried out a literature search of existing reviews on approaches for balancing 
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benefits and risks in decision-making about medicinal products, limiting only to those 
published between year 2000 and 2013. We also included known work by the regulators, 
pharmaceutical companies, and other initiatives. Publications were searched for and selected 
by four independent reviewers. Reviewers revised and discussed each other’s work for 
completeness. We summarized existing reviews and various developments in benefit-risk 
assessment methodologies from various groups worldwide with the intent to provide an index 
of resources in this growing body of research.  
 
We grouped the materials into structured resources on benefit-risk assessment to guide 
statisticians in the learning process of understanding and selecting a useful set of 
methodologies. We highlighted the methodologies that were discussed in the original 
publications and the essence of their recommendations, if any. Finally, we discuss the impact 
the emerging initiatives have on various stakeholders involved in drug decision-making. We 
focus on the changes, current and potential applications of the formal benefit-risk assessment 
methodologies for statisticians in the pharmaceutical industry through the different stages of 
the pharmaceutical product life cycle. 
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Table 1 provides technical terminologies used in this article. 
 
Results 
This section provides an overview of introductory materials, essential materials, special 
interest publications for the benefit-risk assessment, and further information and initiatives. 
The toolkit of available methodologies is then discussed. 
 
Introductory materials to structured benefit-risk assessment  
For those who are not familiar with benefit-risk assessment, there are a number of 
publications that can be used as an introduction to the topic. As introductory materials (Table 
2), we recommend the special issue of the Regulatory Rapporteur,
16
 and two short reviews on 
quantitative benefit-risk methods.
17,18
 
The special issue of the Regulatory Rapporteur
16
 was dedicated to benefit-risk and provided a 
good summary to date from a regulator’s perspective,
19
 and an industry’s perspective.
20
 This 
special issue acknowledges that although qualitative judgments have been used in benefit-risk 
decision-making of medical products, quantitative methods may be needed to deal with the 
challenges posed by the consistency, transparency and predictability of making qualitative 
decisions. The two short reviews on quantitative benefit-risk methods would be suitable for 
statisticians (and others) who are new to the field.
17
 Guo et al., from the International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR) working group, recommend that 
new drug therapy evaluations consider the use of multiple benefit-risk approaches across 
different therapeutic indications and treatment populations.
17
 Puhan et al. provide a 
framework for organizing and selecting quantitative methods for use in a benefit-risk 
assessment.
18
 
 
Pivotal work on benefit-risk assessment methods  
More substantial pivotal work on benefit-risk assessment methods (Table 3) had been carried 
out in various multidisciplinary initiatives including the European Medicine Agency (EMA) 
Benefit-risk Methodology Project,
21
 the Innovative Medicines Initiative 
Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium 
(IMI-PROTECT) Benefit-Risk Integration and Representation
22
 and the Centre for 
Innovation in Regulatory Science (CIRS) Unified Methodologies for Benefit-Risk 
Assessment (UMBRA).
23
  
 
The EMA reviewed the benefit-risk assessment methods in a theoretical and empirical 
context. They appraised each method’s usefulness to the regulators, considering decisions at 
both pre- and post-approval stages of medical products.
9
 Recommended methods went 
through field testing to assess their feasibility and to gain insights into potential practical 
barriers,
24
 which were later further developed and tested for use in a regulatory setting.
25
 
 
The IMI-PROTECT Work Package 5 (WP5) on Benefit-Risk Integration and Representation 
performed a review on 47 benefit-risk assessment methodologies and classified them into 
benefit-risk frameworks, metric indices for BR assessment, estimation techniques and utility 
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survey techniques, based on their principle and purpose.
12,26
 Mt-Isa et al. recommend 13 
methods to be of sufficient variety and should be considered further in real-life benefit-risk 
assessment.
12,26
 Several case studies used publically available data to test the recommended 
methods in order to assess their practicalities when applied to real-life decision problems of 
pharmaceutical products with delicate benefit-risk balance.
27-35
 The key summary and lessons 
learned from testing the methods in case studies were distilled into a final set of 
recommendations in a roadmap of benefit-risk assessment stages.
14
 WP5 also conducted a 
two-part review on the use of visualizations in benefit-risk assessment,
36
 and the suitability of 
visual display for communicating benefit-risk assessment to various stakeholders.
37
 The 
second part of the review also discusses topical issues including the use of non-verbal and 
numerical representation of benefits and risks, and the use of interactive “dashboards”
13
 for 
presenting benefit-risk information.
37
 
 
CIRS UMBRA initiative coordinates development of benefit-risk assessment methods that 
can be used internationally during the drug development, regulatory review and post-approval 
periods.
23,38
 Its goal is to establish common elements across the different methodologies 
(best-in class components) to enable a consensus on a scientifically acceptable framework for 
making benefit-risk decisions. An eight-step assessment framework, largely developing on 
the Benefit-Risk Action Team (BRAT) framework,
39,40
 was proposed and subjected to 
prospective evaluations in 2013.
41
 
 
Special interest publications 
There are other resources on benefit-risk assessment that we could not review here in 
sufficient detail that might be of interest to some readers (Table 4), but many of which 
already overlap with previously mentioned reviews. For instance, the Medicine and 
Healthcare Products Regulatory Agency (MHRA) in the UK has some resources on benefit-
risk assessment: from an academic paper on structured quantitative health outcomes 
approach,
42
 and on some methodological issues in benefit-risk decision-making for 
individuals and regulators.
43
 The US Food and Drug Administration (FDA) considers a more 
qualitative approach to benefit-risk assessment encompassing the “bigger picture”, and was 
developed specific to the FDA requirements.
44-46
 The advancement in this field also includes 
some changes to regulations concerning medical devices,
47
 and also methodological research 
on economic evaluation and triage for research prioritization in Health Technology 
Assessments.
48
 Other work in HTA include efforts focused on standardizing multi-criteria 
decision analysis in the economic evaluation framework is being conducted by the EVIDEM 
Collaboration,
49
 and ensuring efficient and sustainable network in Europe that address BRA 
upfront by EUnetHTA.
50
 
 
Further information and initiatives 
Several reviews (Table 5) have also mentioned the Pharmaceutical Research and 
Manufacturers of America Benefit-Risk Action Team (PhRMA BRAT) and the 4-Agency 
Consortium of Canada, Australia, Switzerland and Singapore (CASS). Since their 
introductions, CASS has developed into Consortium on Benefit-Risk Assessment (COBRA); 
and although case studies found PhRMA BRAT framework to be widely acceptable,
20,40,51
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PhRMA selected CIRS to further develop the framework under the auspices of the UMBRA 
initiative 
23
. The Dutch Escher project endeavours to stimulate the reform of the regulatory of 
pharmaceutical products.
52
 Escher’s Aggregate Data Drug Information System (ADDIS) sub-
project demonstrates a software package that could automate a seamless evidence synthesis 
and benefit-risk assessment.
53
 Another IMI funded initiative, the European Programme in 
Pharmacovigilance and Pharmacoepidemiology (Eu2P), offers courses allied to benefit-risk 
assessment of medicines, drawing on previous investments and research expertise.
54
 The 
EFSPI BR SIG equivalent, the Quantitative Sciences in Pharmaceutical Industry (QSPI) 
group, is also working towards the same goal in advocating the scientific and regulatory 
issues of benefit-risk assessment in the United States.
55
 
 
Toolkit of advocated benefit-risk assessment methodologies 
There is no firm consensus on a single methodology that can be used for every decision 
problem.
17,56
 It is therefore, in our view, better to equip benefit-risk assessors (statisticians, 
regulators, clinicians) with a toolkit of resources that will foster the understanding of 
methodology choices. 
 
The EMA proposed that an appraisal of a benefit-risk assessment methodology includes the 
assessment of its logical soundness, comprehensiveness, acceptability of results, practicality 
and generativeness.
9
 These criteria help to ensure that an assessor could appropriately justify 
the methodology choices. According to the IMI-PROTECT Work Package 5, who cultivated 
these criteria in their review, a benefit-risk methodology should be transparent, ensure the use 
of good quality of evidence, address uncertainty and biases, allow meaningful benefit-risk 
integration, result in interpretable results and eliminate any potential misleading 
communications.
12
  
 
Table 6 provides an overview of the qualitative methods and Table 7 provides an overview of 
the quantitative methods, which are referenced in the reviews; where details of the 
methodologies are also available.
26,57
 It was suggested by IMI-PROTECT WP5 to test 13 
methodologies in future benefit-risk assessment: PrOACT-URL, BRAT, MCDA, SMAA, 
NNT/NNH, Impact numbers, QALY, Q-TWiST, INHB, BRR, probabilistic simulations, 
MTC, and DCE (see Table 6 and Table 7 for abbreviations), and further classifications of 
methodologies can be found in the PROTECT WP5 report.
12
 Other methodologies may also 
be suitable depending on the situations and must not blindly be dismissed.
12,14,26
  The choice 
of methodologies may depend on different therapeutic area (e.g. depending on use of time-to-
event statistics), time of appraisal and regulatory requests. The EMA BR project suggested 
that MCDA, Bayesian statistics and decision trees are the most comprehensive among the 
quantitative methodologies.
9
 Other useful methodologies include probabilistic simulation, 
Bayesian belief networks, Markov processes, and QALYs/DALYs.
9
 
 
The combination of evidence data with preference weights in methods such as MCDA and 
SMAA may lead to high quality and relevant decisions but requires more effort and 
resources, and much attention should be paid to transparency when using these types of 
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methods.
14
 Due to the complexity of incorporating weights into decision-making formally, 
formal estimation of weights should only be considered in complex benefit-risk decision 
problems. Related to this, there is emerging interest and concern to incorporate preference 
weights from patients and public in benefit-risk decision-making of pharmaceutical products. 
In any case, all benefit-risk initiatives agree that a systematic use of a qualitative framework, 
including supporting other quantitative methodologies, is needed to increase the transparency 
of a benefit-risk assessment. 
 
Discussion 
This review concurs that there is no consensus and not a one-size-fits-all methodology that 
can be used for every decision problem,
17,56
 and there is often the need for multiple 
methodologies be used in sync.
14
 The fast-changing landscape of regulatory benefit-risk 
assessment, including FDA adoption of PBRER,
1
 suggests the need for systematic learning to 
efficiently identify and fill knowledge gaps in the area. Although the use of quantitative or 
semi-quantitative assessments to weight benefits against risks is explicitly mentioned,
1,2
 
formal benefit-risk assessment methodologies are not currently specified. Consequently, 
those who perform or review benefit-risk assessments for regulatory submissions often find 
themselves putting more effort than needed to ensure proper conduct and documentations. 
This article carefully structures the key materials in benefit-risk assessment up to 2013, and is 
therefore intended to save valuable resources by preventing duplication of efforts and 
promoting efficient learning. 
 
Opportunities for statisticians in the pharmaceutical industry 
There are opportunities, for statisticians in the pharmaceutical industry especially, to 
champion the BRA methodologies use throughout the pharmaceutical product lifecycle. 
Assessing the balance between benefits and risks is a complex task driven by the different 
favorable and unfavorable effects of a drug, the uncertainty about these benefits and risks, 
and varying preferences of different stakeholders.
21
. This may require pharmaceutical 
statisticians to continuously adapt to new techniques and methodologies to handle, for 
example, sources of uncertainties, endpoints that are causally dependent or even double-count 
the same event, efficacy and safety measures defined over different populations or over 
different time periods, or to pool data from different sources (mainly clinical and post-
marketing data). Because of these needs, benefit-risk special interest groups (BR-SIGs) 
within the pharmaceutical industry, like ours, are formed. The establishment of BR-SIGs 
means that pharmaceutical statisticians from various companies would have access to a 
common platform to exchange knowledge and to advance the topic within the industry. Such 
collaboration is fundamental, as a first step, to move towards the harmonization of structured 
BRA. 
 
Benefit-risk assessment is important to the pharmaceutical industry itself throughout the drug 
development stages. At discovery stage, it is important to identify those compounds for 
which the estimated potential benefit-risk balance for the preferred mode of action for the 
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target population is positive. For example, in phases I and IIA trials, the benefit and risk data 
can be utilized to assist in “go” or “no-go” decisions. The probability of phase III trial 
program success can be improved by first assessing the benefit-risk profile estimated based 
on earlier phases. By indicating, in phase IIB or III, the elements that are missing in the 
benefit-risk assessment, the design of clinical trials can be set up to incorporate structured 
BRA methodologies to increase transparency and thence support these decisions seamlessly.  
 
Common understanding of BRA methodologies through systematic knowledge-based 
sources, like this article, can further facilitate communication among stakeholders. 
 
Implications to other stakeholders 
Successful drugs are drugs that demonstrate their value to all stakeholders, including patients, 
physicians, regulators, Health Technology Assessment bodies (HTAs), and payers.  
 
For patients, the primary decision is whether or not to take a particular treatment for their 
medical conditions, hence it is important that patients understand the extent of benefits and 
risks associated with the treatment options. Several methodologies also directly allow patients 
to be involved at much earlier stages of the benefit-risk assessment, and therefore the final 
benefit-risk balance would be of more relevance. Structured BRA methodologies tailored to 
patient communication could help physicians to advise patients better, moving from 
consultative towards collaborative healthcare decision-making. In reality, the price of 
treatments may play a major role to patients depending on the healthcare system, and should 
also be addressed as part of the decision-making.  
 
For payers, the budget impact of benefits and costs is important. This means that a reduction 
in a laboratory parameter is only important when this also results in reduction of outcomes 
influencing their budget. As such, benefits and risks should be assessed in terms of costs.  As 
a consequence, payers would be interested in how well the drug works in the population, in 
real practice versus standard of care. The constraint on costs in BRA presents additional 
complexity to payers when determining the benefit-risk balance. 
 
HTA bodies compare the incremental benefits and risks versus the costs related to different 
comparators on the market. The National Institute for Health and Care Excellence in the UK 
provides guidelines on incorporating health state utility values in economic evaluations, 
including mapping methods (TSD10),
58,59
 alternatives to the well-accepted EQ-5D index 
(TSD11),
60,61
 and their use in decision models (TSD12).
62,63
 Moreover, cost-effectiveness 
models evaluating benefits and risks against monetary costs are already used worldwide. 
Recent initiatives put these cost-effectiveness models within the context of benefit-risk 
assessment, with aim to provide more integrated tools.
49,50
  
 
Regulators assess benefit-risk balance of healthcare products and medicines for marketing 
authorization and as part of continuous safety monitoring.
64
 EMA states that, “regulatory 
assessors will be in a better position to judge the benefit-risk balance when structured 
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evaluations are submitted, because a structured evaluation induces a gain in transparency, 
communicability, auditability and quality.”
9,65
 Moreover, both EMA and FDA will 
incorporate a structured benefit-risk assessment into the regulatory review process;
21,66
 and 
this article could contribute towards the bigger picture in terms of contextualizing concurrent 
initiatives worldwide. 
 
Conclusions 
The use of a structured benefit-risk assessment at the different stages of the product lifecycle 
may offer important added value to ensure better transparency, robustness and a justifiable 
decision-making process. 
 
We hope that the overview and toolkit of resources provided will not only serve as starting 
material, but will be used to facilitate further discussion and to reach consensus on which 
methods to use for a particular situation. For this, the different initiatives in which regulators 
and the pharmaceutical industry collaborate and better communications and understanding 
related to benefit-risk assessments are very important. 
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Table 1 Glossary of terminologies 
Terminology Description 
Benefit The positive results of a given treatment for an individual or a population. 
(i.e. efficacy, convenience, or even quality of life).
12
 
Dashboard A dashboard is a visual display of the most important information needed to 
achieve one or more objectives; consolidated and arranged on a single 
screen so the information can be monitored at a glance.
13
 
Framework A structured stepwise approach to perform a task.
14
 
Qualitative The system is a purely qualitative framework based on internal experts or 
management making a “gut decision” on the benefit–risk profile of each 
product and providing a conclusion. The final decision will be exercised 
based on Expert Judgment.
15
 
Quantitative The system is a fully quantitative model which includes a benefit–risk 
balance for a new medicine, and is applied across study data and 
contributing opinions. The conclusion is based on the cumulative outcome 
from this single system. The final decision will be exercised based on Expert 
Judgment.
15
 
Risk The unfavourable negative results (adverse outcomes) of a given treatment 
for an individual or a population in terms of probability of occurrence 
having considered the magnitude of severity.
12
 
 
  
Page 17 of 23
http://mc.manuscriptcentral.com/pst-wiley
Pharmaceutical Statistics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17 
 
 
 
Table 2 Introductory materials 
Publication Comment 
Special issue Regulatory Rapporteur (2012) 
http://www.topra.org/regulatory-rapporteur-june-2012 
Evaluating benefit-risk: An Agency Perspective 
 
Evaluating benefit-risk during and beyond drug 
development: An Industry View 
Up to date summary from 
regulator’s perspective and 
industry’s perspective 
 
 
 
Guo et al (2010): A Review of Quantitative Risk-
Benefit Methodologies for Assessing Drug Safety and 
Efficacy – Report of the ISPOR Risk-benefit 
Management Working Group 
Recommend the use of multiple 
benefit-risk approaches across 
different therapeutic indications 
and treatment populations 
Puhan et al (2012): A framework for organizing and 
selecting quantitative approaches for benefit-harm 
assessment 
A framework organizing and 
selecting quantitative methods 
 
  
Page 18 of 23
http://mc.manuscriptcentral.com/pst-wiley
Pharmaceutical Statistics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
 
Table 3 Essential materials 
Publication Comment 
EMA: Work packages  Methods appraisal, field testing and 
use in regulatory setting 
IMI Protect: Work package 5 and other papers; 
 
47 benefit-risk methods assessed 
and classified. 13 methods 
considered further. Case studies 
and recommendations 
CIRS UMBRA: Standardizing the Benefit-Risk 
Assessment of New Medicines; Building the Benefit-
Risk Toolbox Workshop 
Target is consensus of scientifically 
acceptable framework 
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Table 4 Special interest publications 
Special interest publications 
MHRA:  
• Garisson et al: Assessing A Structured, Quantitative Health Outcomes Approach To 
Drug Risk-Benefit Analysis 
• Benefit: Risk Decision-Making for Individuals and Drug Regulators 
FDA: 
• A United States Regulator’s Perspective on Risk-Benefit Considerations 
• Benefit-Risk Considerations in CDER: Development of a Qualitative Framework 
• Factors to Consider When Making Benefit-Risk Determinations in Medical Device 
Premarket Approval and De Novo Classifications 
• Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision 
Making, Draft PDUFA V Implementation Plan – February 2013 
NHS: 
• Prioritisation of health technology assessment. The PATHS model: methods and 
case studies 
EVIDEM: 
• Provides a framework of multi-criteria health economic evaluation using the multi-
criteria decision analysis based on evidence  
EUnetHTA: 
• Working with the regulators to ensure benefit and risk questions are addressed at 
much earlier stage to better incorporate the aspect in health technology assessment 
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Table 5 Further information and initiatives 
Futher information and initiatives Comments 
PhRMA BRAT: Development of a framework for 
enhancing the transparency, reproducibility and 
communication of the benefit-risk balance of 
pharmaceutical products. Application of the BRAT 
framework to case studies: observations and insights 
Further development framework by 
UMBRA initiative 
 
 
 
 
CASS - COBRA 
 
Developed a framework “proforma” 
 
Dutch Escher project Seamless evidence synthesis and 
benefit risk assessment 
European Programme in Pharmacovigilance and 
Pharmacoepidemiology (Eu2P) 
Courses benefit risk 
QSPI 
EFSPI BR SIG 
Special interest groups of EFSPI and 
QSPI related to benefit risk 
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Table 6: Qualitative methods referenced in reviews 
Qualitative frameworks EMA PROTECT TOPRA 
Ashby and Smith Framework (ASF) x 
Benefit Risk Action Team (BRAT) x x* x 
CMR Health Canada, Australia’s Therapeutic Goods 
Administration, SwissMedic, and Singapore Health 
Science Authority (CMR-CASS) x x x 
Value tree  x x x 
FDA Benefit Risk Framework (FDA BRF) x x x 
Problem, Objectives, Alternatives, Consequences, Trade-
offs, Uncertainty, Risk, and Linked decisions framework 
(PrOACT-URL) x x* x 
Unified Methodologies for Benefit-Risk Assessment  x  
Southeast Asia Benefit-Risk Evaluation  x  
Consortium on Benefit-Risk Assessment  x  
* Methodologies that were suggested being useful for future benefit-risk assessments 
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Table 7: Quantitative methods referenced in reviews 
Quantitative methods EMA Puhan Guo PROTECT TOPRA 
Adverse Event adjusted Number Needed to 
Treat (AE-NNT) x 
Bayesian belief networks (BBN) x* 
Bayesian statistics x* 
Beckmann model x 
Benefit-less-risk analysis (BLRA) x x x 
Benefit-Risk Ratio (BRR) x* 
Boers table x 
Cross Design Synthesis (CDS) x 
Conjoint analysis (CA) x x 
Contingent valuation x x 
Confidence Profile Method (CPM) x 
Clinical Utility Index (CUI) x 
Directed Acyclic Graphs (DAG) x 
Discrete Choice Experiment (DCE)    x*  
Decision tree and influence/relevance diagrams x*   x x 
Desirability Index (DI) x 
Discrete event simulation x 
Evidence based benefit and risk model x x 
Gail x 
Global Benefit Risk (GBR) x 
Health Adjusted Life Years (HALE) x 
Impact numbers x* 
Incremental net health benefit (INHB) x x x x* x 
Indirect Treatment Comparison (ITC) x* 
Kaplan Meier estimator x 
Markov process x* 
Maximum acceptable risk (MAR)/Stated 
preference method (SPM) x x x x x 
Markov Decision Process (MDP) x 
Minimum clinical efficacy (MCE) x x x 
Mixed Treatment Comparison (MTC) x* 
Multi-criteria decision analysis (MCDA) x* x x x* x 
Net Efficacy Adjusted for Risk (NEAR) x 
Net Clinical Benefit (NCB) x x 
Number needed to treat (NNT)/ Number needed 
to harm (NNH) x x x x* 
Principle of threes x x 
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Probabilistic simulation methods (PSM) x* x x x* 
Quality/ Disability Adjusted Life Years 
(QALY/DALY) x* x* x 
Quality-adjusted Time without Symptoms and 
Toxicity (Q-TWIST) x x x* 
Quantitative Framework for Risk and Benefit 
Assessment (QFRBA) x x 
Relative value adjusted number needed to treat 
(RV-NNT) x x 
Risk–benefit contour (RBC) x x 
Risk–benefit plane (RBP) / risk–benefit 
acceptability threshold (RBAT) x x 
Sarac’s Benefit Risk Assessment (SBRAM) x 
Stochastic Multi-criteria Acceptability Analysis 
(SMAA) x* 
System dynamics x 
Transparent Uniform Risk Benefit Overview 
(TURBO) x x x 
Utility- and Time-adjusted Number Needed to 
Treat (UT-NNT) x 
* Methodologies that were suggested being useful for future benefit-risk assessments 
 
 
 
 
 
 
Page 24 of 23
http://mc.manuscriptcentral.com/pst-wiley
Pharmaceutical Statistics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
